Advertisement
Sigma-Aldrich
Sigma-Aldrich

The Scientist

» biotech

Most Recent

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

image: Week in Review: August 26–30

Week in Review: August 26–30

By | August 30, 2013

New model for neurodevelopment; more biotechs going public; how a virus jumped from mammals to birds; statin side effect linked to genetic variant

0 Comments

image: Opinion: AIA Does Not Discriminate

Opinion: AIA Does Not Discriminate

By | August 21, 2013

The America Invents Act (AIA) was a step in the right direction for US competitiveness and open innovation.

5 Comments

image: BPTW: By The Numbers

BPTW: By The Numbers

By | June 1, 2013

Take a closer look at some of the statistics generated by The Scientist's Best Place to Work Industry 2013 survey.

0 Comments

image: Best Places to Work Industry 2013

Best Places to Work Industry 2013

By | June 1, 2013

Our final survey of the life-science industry workplace highlights the companies—small and large, domestic and international—that are making their researchers feel valued and at home.

2 Comments

image: Start It Up

Start It Up

By | April 1, 2013

Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.

1 Comment

image: Philip Low: Sleep Analyzer

Philip Low: Sleep Analyzer

By | January 1, 2013

Founder, Chairman, and CEO, NeuroVigil, Age: 33

2 Comments

image: Single Patent for EU

Single Patent for EU

By | December 12, 2012

After decades of political wrangling, the European Union is poised to introduce a single patent system to reduce red tape and application costs for researchers and companies.

1 Comment

image: DNA for the Masses

DNA for the Masses

By | October 31, 2012

An Israeli company plans to synthesize DNA on demand for anyone, including those outside of research labs.  

1 Comment

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement